conserved motifs and helices in 5HT2BR: Advances drug discovery and therapeutic approach towards drug resistant Cell-trafficking impairment in disease-associated LPA6 missense mutants and a potential pharmacoperone therapy

Regulating Agonist and Antagonist Binding in the Active Site of a Novel Target 5HT2BR Against Drug-Resistant GPCRs in Oncology and Immunology A2aR on lung adenocarcinoma cells: A novel target for cancer therapy

G-protein coupled receptors (GPCRs) have been largely targeted in a wide range of diseases, but few therapies

effector that activates Rab27B Targeting of insulin receptor endocytosis as a treatment to insulin resistance the Treatment of Insomnia OMass Therapeutics Releases First Protein Structures in PDB, Advances Lupus Therapy

Structural characterization of biologics, such as vaccines, viral vectors, and gene therapy agents, has

Currently-approved treatments have improved patient outcomes, but therapies to stop or reverse HF are

optogenetically functionalized Drosophila dopamine receptors Targeting CB2R in astrocytes for Parkinson's disease therapy Therapeutics Enters Capsid License Agreement and Strategic Collaboration with Novartis to Advance Novel Gene Therapies

GPR35 ligands that selectively modulate GPR35-transducer interactions and allow for mechanism-based therapies

Src Family Kinases on YAP and ERK Activation in Pancreatic Cancer Cells: Implications for Targeted Therapy

opportunities in the translational development of these findings to generate safe and effective precision therapies

Therefore, a better understanding of the pathophysiology of hepatic fibrosis and the development of related therapies

Register now for the GPCR Drug Discovery Conference and unlock incredible savings of $200 using the Discovery Flavors of GPCR signaling bias Glucagon-like peptide-1 receptor: mechanisms and advances in therapy

If you're already registered, kindly use the provided form to submit your poster abstracts. You don't need to be registered to participate. PRL3-zumab humanized antibody Activation of PI3K/Akt pathway by G protein-coupled receptor 37 promotes resistance

key biological process but also provides a valuable map for pharmaceutical researchers to design new therapies

Wins Biotech Company of the Year and Financing Deal of the Year at the Citeline Japan Awards 2024 GPCR therapies

Collaboration for Development and Commercialization of Voyager’s GBA1 Program and Other Next-Generation Gene Therapies

Directors GPCR Therapeutics launches multiple myeloma trial Salipro Biotech is attending the 3rd Advanced Therapy

AbbVie to acquire neuroscience drugmaker Cerevel Therapeutics for $8.7 billion FDA approves two gene therapies

Immunology Metabolic crosstalk: Extracellular ATP and the tumor microenvironment in cancer progression and therapy

Respiratory infections predominate after day 100 following B-cell maturation antigen-directed CAR T-cell therapy

bioinformatics, and clinical research has opened new avenues for exploring GPCR biology, developing targeted therapies

C265 augments β2AR protein kinase A signaling, enables β2AR nitric oxide (NO) signaling, renders mice resistant

of potential inhibitors of GPR52 using docking and biased sampling method for Huntington's disease therapy

conservation across distant species Industry News Avantor's (AVTR) New Offerings to Aid Cell and Gene Therapy

structural dynamics approach for identification of potential agonists of FFAR4 for type 2 diabetes mellitus therapy

concentrations in Caenorhabditis elegans Comparison of infectious complications with BCMA-directed therapies

β-adrenergic-like octopamine receptor (Octβ2R), is the unique target of amitraz, but the honeybee Octβ2R resists

Drug Hunter GPCR Therapeutics Announces Publication in Nature Scientific Reports on Novel Anticancer Therapy